GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022
21 mars 2022 09h00 HE
|
GeoVax, Inc.
Presentation to Focus on GEO-CM02 Being Developed as aUniversal Vaccine to Address Evolving SARS-CoV-2 Variants ATLANTA, GA, March 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...
GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials
14 mars 2022 09h00 HE
|
GeoVax, Inc.
Comparative Trial Against Pfizer/BioNTech Vaccine Among Immunocompromised PatientsBooster to Pfizer/BioNTech or Moderna Vaccines Among Healthy PatientsATLANTA, GA, March 14, 2022 (GLOBE NEWSWIRE) --...
Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows it Produced Robust Antibodies and T cells Against SARS-CoV-2
10 mars 2022 09h00 HE
|
GeoVax, Inc.
The investigational vaccine is now being used in Phase 2 trials for immunocompromised patients and as a booster for healthy adult volunteers LOS ANGELES and ATLANTA, March 10, 2022 (GLOBE NEWSWIRE)...
GeoVax to Participate in Benzinga Biotech Small Cap Conference
17 mars 2021 09h00 HE
|
GeoVax, Inc.
GeoVax Chairman & CEO David Dodd to Present Corporate OverviewGeoVax CSO, Mark Newman, PhD, to Participate in Immuno-Oncology Panel Discussion ATLANTA, GA, March 17, 2021 (GLOBE NEWSWIRE) --...
GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients
24 août 2020 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Aug. 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases...
GeoVax Announces 100% Protection Data from Marburg Virus Vaccine Study
29 juil. 2019 09h00 HE
|
GeoVax, Inc.
Study Data Adds to Similar Efficacy Previously Reported for GeoVax’s Ebola and Lassa Fever Vaccines ATLANTA, GA, July 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB:...
GeoVax and Emory University to Collaborate on HPV Therapeutic Program for Head and Neck Cancers
30 juil. 2018 09h00 HE
|
GeoVax, Inc.
GeoVax Continues Expansion of its MVA-VLP Vaccine Pipeline with Multiple Collaborations in Infectious Disease and Immuno-oncology ATLANTA, GA, July 30, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc....
GeoVax to Present at the American Society for Virology 2018 Annual Meeting
09 juil. 2018 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, July 09, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), winner of the 2018 “Best Biotech” at the Vaccine Industry Excellence (ViE) Awards during the World Vaccine Congress,...
GeoVax Reports 2018 First Quarter Financial Results and Development Program Updates
03 mai 2018 13h00 HE
|
GeoVax, Inc.
ATLANTA, May 03, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB:GOVX), a biotechnology company developing human vaccines, today announced its financial results for the three months ended March...
GeoVax to Collaborate with the U.S. Naval Research Laboratory On Development of Lassa Fever Biosensors
12 déc. 2017 09h00 HE
|
GeoVax, Inc.
Atlanta, GA, Dec. 12, 2017 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with the U.S. Naval...